Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32646357,flow rate,"Samples were eluted from the column at the flow rate of 1.4 mL/min using a mobile phase containing 0.2% triethylamine in water (pH 3.4 with formic acid): acetonitrile (45:55, v/v).",Simple and Fast Determination of Terbinafine in Human Urine by Dilute and Shoot HPLC-DAD Using a Core-Shell Column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32646357/),[ml] / [min],1.4,4144,DB00857,Terbinafine
,32646357,limit of detection,The limit of detection was 12.60 ng/mL.,Simple and Fast Determination of Terbinafine in Human Urine by Dilute and Shoot HPLC-DAD Using a Core-Shell Column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32646357/),[ng] / [ml],12.60,4145,DB00857,Terbinafine
,17124578,peak plasma concentration (C(max)),"Compared with the placebo, terbinafine treatment significantly increased the peak plasma concentration (C(max)) of paroxetine, by 1.9-fold (6.4 +/- 2.4 versus 12.1 +/- 2.9 ng/ml, p < 0.001), and the area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)] of paroxetine by 2.5-fold (127 +/- 67 vs 318 +/- 102 ng/ml, p < 0.001).",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),[ng] / [ml],6.4,5419,DB00857,Terbinafine
,17124578,peak plasma concentration (C(max)),"Compared with the placebo, terbinafine treatment significantly increased the peak plasma concentration (C(max)) of paroxetine, by 1.9-fold (6.4 +/- 2.4 versus 12.1 +/- 2.9 ng/ml, p < 0.001), and the area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)] of paroxetine by 2.5-fold (127 +/- 67 vs 318 +/- 102 ng/ml, p < 0.001).",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),[ng] / [ml],12.1,5420,DB00857,Terbinafine
,17124578,area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)],"Compared with the placebo, terbinafine treatment significantly increased the peak plasma concentration (C(max)) of paroxetine, by 1.9-fold (6.4 +/- 2.4 versus 12.1 +/- 2.9 ng/ml, p < 0.001), and the area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)] of paroxetine by 2.5-fold (127 +/- 67 vs 318 +/- 102 ng/ml, p < 0.001).",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),[ng] / [ml],127,5421,DB00857,Terbinafine
,17124578,area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)],"Compared with the placebo, terbinafine treatment significantly increased the peak plasma concentration (C(max)) of paroxetine, by 1.9-fold (6.4 +/- 2.4 versus 12.1 +/- 2.9 ng/ml, p < 0.001), and the area under the plasma concentration-time curve from zero to 48 h [AUC (0-48)] of paroxetine by 2.5-fold (127 +/- 67 vs 318 +/- 102 ng/ml, p < 0.001).",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),[ng] / [ml],318,5422,DB00857,Terbinafine
,17124578,Elimination half-life,"Elimination half-life differed significantly (15.3 +/- 2.4 vs 22.7 +/- 8.8 h, p < 0.05), although the magnitude of alteration (1.4-fold) was smaller than C(max )or AUC.",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),h,15.3,5423,DB00857,Terbinafine
,17124578,Elimination half-life,"Elimination half-life differed significantly (15.3 +/- 2.4 vs 22.7 +/- 8.8 h, p < 0.05), although the magnitude of alteration (1.4-fold) was smaller than C(max )or AUC.",Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124578/),h,22.7,5424,DB00857,Terbinafine
,23718650,maximum concentration,"After oral administration of terbinafine, the maximum concentration for the remaining 5 fed birds ranged from 109 to 671 ng/mL, half-life ranged from 6 to 13.5 hours, and time to the maximum concentration ranged from 2 to 8 hours.",Pharmacokinetics of terbinafine after oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23718650/),[ng] / [ml],109 to 671,11284,DB00857,Terbinafine
,23718650,half-life,"After oral administration of terbinafine, the maximum concentration for the remaining 5 fed birds ranged from 109 to 671 ng/mL, half-life ranged from 6 to 13.5 hours, and time to the maximum concentration ranged from 2 to 8 hours.",Pharmacokinetics of terbinafine after oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23718650/),h,6 to 13.5,11285,DB00857,Terbinafine
,23718650,time to the maximum concentration,"After oral administration of terbinafine, the maximum concentration for the remaining 5 fed birds ranged from 109 to 671 ng/mL, half-life ranged from 6 to 13.5 hours, and time to the maximum concentration ranged from 2 to 8 hours.",Pharmacokinetics of terbinafine after oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23718650/),h,2 to 8,11286,DB00857,Terbinafine
,25600982,area under the curve (AUC0-48hrs),The optimum formulation of terbinafine SMEDDS when orally administered to rat with and without chylomicron flow blocking agent (cycloheximide) showed the area under the curve (AUC0-48hrs) as 10168.17 ng h/ml and 7425.44 ng h/ml respectively indicating the absorption through the lymphatic route.,Development and Pharmacokinetic Evaluation of Industrially Viable Self-microemulsifying Drug Delivery Systems (SMEDDS) for Terbinafine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600982/),[h·ng] / [ml],10168.17,13698,DB00857,Terbinafine
,25600982,area under the curve (AUC0-48hrs),The optimum formulation of terbinafine SMEDDS when orally administered to rat with and without chylomicron flow blocking agent (cycloheximide) showed the area under the curve (AUC0-48hrs) as 10168.17 ng h/ml and 7425.44 ng h/ml respectively indicating the absorption through the lymphatic route.,Development and Pharmacokinetic Evaluation of Industrially Viable Self-microemulsifying Drug Delivery Systems (SMEDDS) for Terbinafine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600982/),[h·ng] / [ml],7425.44,13699,DB00857,Terbinafine
,21492187,half-life,"The half-life (geometric mean) was 8.1 and 8.6 h for horses and Greyhounds, respectively.",Pharmacokinetics of oral terbinafine in horses and Greyhound dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492187/),h,8.1,14544,DB00857,Terbinafine
,21492187,half-life,"The half-life (geometric mean) was 8.1 and 8.6 h for horses and Greyhounds, respectively.",Pharmacokinetics of oral terbinafine in horses and Greyhound dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492187/),h,8.6,14545,DB00857,Terbinafine
,21492187,maximum plasma concentration,"The mean maximum plasma concentration was 0.31 and 4.01 μg/mL for horses and Greyhounds, respectively.",Pharmacokinetics of oral terbinafine in horses and Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492187/),[μg] / [ml],0.31,14546,DB00857,Terbinafine
,21492187,maximum plasma concentration,"The mean maximum plasma concentration was 0.31 and 4.01 μg/mL for horses and Greyhounds, respectively.",Pharmacokinetics of oral terbinafine in horses and Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492187/),[μg] / [ml],4.01,14547,DB00857,Terbinafine
,21492187,area under the curve (to infinity),The area under the curve (to infinity) was 1.793 h·μg/mL for horses and 17.253 h·μg/mL for Greyhounds.,Pharmacokinetics of oral terbinafine in horses and Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492187/),[h·μg] / [ml],1.793,14548,DB00857,Terbinafine
,21492187,area under the curve (to infinity),The area under the curve (to infinity) was 1.793 h·μg/mL for horses and 17.253 h·μg/mL for Greyhounds.,Pharmacokinetics of oral terbinafine in horses and Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492187/),[h·μg] / [ml],17.253,14549,DB00857,Terbinafine
,12412819,C(max),"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[ng] / [ml],19,21697,DB00857,Terbinafine
,12412819,C(max),"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[ng] / [ml],36,21698,DB00857,Terbinafine
,12412819,AUC0-infinity,"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[h·ng] / [ml],482,21699,DB00857,Terbinafine
,12412819,AUC0-infinity,"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[h·ng] / [ml],2383,21700,DB00857,Terbinafine
,1681649,Plasma levels,Plasma levels range between 0.1 and 1.0 micrograms/ml.,"Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681649/),[μg] / [ml],0.1 and 1.0,22112,DB00857,Terbinafine
,1681649,half-life,Elimination of drug from tissue occurs with a half-life of 4 to 5 days and with the potential for drug levels above fungicidal concentrations for dermatophytes for more than 3 weeks.,"Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681649/),d,4 to 5,22113,DB00857,Terbinafine
,22403416,terminal half-life,"After intravenous administration, the terminal half-life and area under the curve from time 0 to infinity were 10.40 ± 4.56 h, 15.20 ± 3.61 h·µg/ml, respectively.",Single dose pharmacokinetics of terbinafine in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403416/),h,10.40,25621,DB00857,Terbinafine
,22403416,area under the curve from time 0 to infinity,"After intravenous administration, the terminal half-life and area under the curve from time 0 to infinity were 10.40 ± 4.56 h, 15.20 ± 3.61 h·µg/ml, respectively.",Single dose pharmacokinetics of terbinafine in cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403416/),[h·μg] / [ml],15.20,25622,DB00857,Terbinafine
,22403416,maximum concentration,"After oral dosing, the mean maximum concentration was 3.22 ± 0.60 µg/ml, reached at 1.33 ± 0.41 h.",Single dose pharmacokinetics of terbinafine in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403416/),[μg] / [ml],3.22,25623,DB00857,Terbinafine
,22403416,terminal half-life,"The terminal half-life, area under the curve from time 0 to infinity and apparent volume of distribution were 8.01 ± 3.46 h, 13.77 ± 4.99 h·µg/ml, 25.63 ± 6.29 l/kg, respectively.",Single dose pharmacokinetics of terbinafine in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403416/),h,8.01,25624,DB00857,Terbinafine
,22403416,area under the curve from time 0 to infinity,"The terminal half-life, area under the curve from time 0 to infinity and apparent volume of distribution were 8.01 ± 3.46 h, 13.77 ± 4.99 h·µg/ml, 25.63 ± 6.29 l/kg, respectively.",Single dose pharmacokinetics of terbinafine in cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403416/),[h·μg] / [ml],13.77,25625,DB00857,Terbinafine
,22403416,apparent volume of distribution,"The terminal half-life, area under the curve from time 0 to infinity and apparent volume of distribution were 8.01 ± 3.46 h, 13.77 ± 4.99 h·µg/ml, 25.63 ± 6.29 l/kg, respectively.",Single dose pharmacokinetics of terbinafine in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403416/),[l] / [kg],25.63,25626,DB00857,Terbinafine
,22403416,absolute bioavailability,The absolute bioavailability of terbinafine hydrochloride tablets after oral administration was 31.00 ± 10.85%.,Single dose pharmacokinetics of terbinafine in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403416/),%,31.00,25627,DB00857,Terbinafine
,20461049,bioavailability,The drug is highly lipophilic and keratophilic and is highly bound to plasma protein (>90%) with a bioavailability of 70% to 80%.,Update on antifungal therapy with terbinafine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20461049/),%,70,48118,DB00857,Terbinafine
,20461049,bioavailability,The drug is highly lipophilic and keratophilic and is highly bound to plasma protein (>90%) with a bioavailability of 70% to 80%.,Update on antifungal therapy with terbinafine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20461049/),%,80,48119,DB00857,Terbinafine
,8176256,peak blood concentration,"The mean peak blood concentration of cyclosporin when taken alone was 958 micrograms/l, and 822 when taken with terbinafine.",Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),[μg] / [l],958,51989,DB00857,Terbinafine
,8176256,peak blood concentration,"The mean peak blood concentration of cyclosporin when taken alone was 958 micrograms/l, and 822 when taken with terbinafine.",Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),,822,51990,DB00857,Terbinafine
,8176256,area under the curve,The mean area under the curve for cyclosporin was 4207 micrograms/l/h when taken alone and 3665 when taken with terbinafine.,Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),[μg] / [h·l],4207,51991,DB00857,Terbinafine
,8176256,area under the curve,The mean area under the curve for cyclosporin was 4207 micrograms/l/h when taken alone and 3665 when taken with terbinafine.,Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),,3665,51992,DB00857,Terbinafine
,8176256,absorption half-life,"The mean absorption half-life for cyclosporin when taken alone was 0.29 h, and 0.33 when taken with terbinafine.",Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),h,0.29,51993,DB00857,Terbinafine
,8176256,absorption half-life,"The mean absorption half-life for cyclosporin when taken alone was 0.29 h, and 0.33 when taken with terbinafine.",Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),,0.33,51994,DB00857,Terbinafine
,16220086,Cmax,"Absolute estimates of Cmax and area under the concentration curve (AUC)0-24 were comparable between children and adults for the administered dose; however, children demonstrated significantly lower estimates of exposure when dose was corrected for weight (Cmax SS 200 +/- 104 versus 454 +/- 185 ng/mL per mg/kg dose, P < 0.01; AUCSS: 1110 +/- 640 versus 2756 +/- 1775 ng*h/mL per mg/kg dose, P < 0.01).",Pharmacokinetics of terbinafine in young children treated for tinea capitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220086/),[ng] / [kg·mg·ml],200,62282,DB00857,Terbinafine
,16220086,Cmax,"Absolute estimates of Cmax and area under the concentration curve (AUC)0-24 were comparable between children and adults for the administered dose; however, children demonstrated significantly lower estimates of exposure when dose was corrected for weight (Cmax SS 200 +/- 104 versus 454 +/- 185 ng/mL per mg/kg dose, P < 0.01; AUCSS: 1110 +/- 640 versus 2756 +/- 1775 ng*h/mL per mg/kg dose, P < 0.01).",Pharmacokinetics of terbinafine in young children treated for tinea capitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220086/),[ng] / [kg·mg·ml],454,62283,DB00857,Terbinafine
,16220086,AUCSS,"Absolute estimates of Cmax and area under the concentration curve (AUC)0-24 were comparable between children and adults for the administered dose; however, children demonstrated significantly lower estimates of exposure when dose was corrected for weight (Cmax SS 200 +/- 104 versus 454 +/- 185 ng/mL per mg/kg dose, P < 0.01; AUCSS: 1110 +/- 640 versus 2756 +/- 1775 ng*h/mL per mg/kg dose, P < 0.01).",Pharmacokinetics of terbinafine in young children treated for tinea capitis. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220086/),[h·ng] / [kg·mg·ml],1110,62284,DB00857,Terbinafine
,16220086,AUCSS,"Absolute estimates of Cmax and area under the concentration curve (AUC)0-24 were comparable between children and adults for the administered dose; however, children demonstrated significantly lower estimates of exposure when dose was corrected for weight (Cmax SS 200 +/- 104 versus 454 +/- 185 ng/mL per mg/kg dose, P < 0.01; AUCSS: 1110 +/- 640 versus 2756 +/- 1775 ng*h/mL per mg/kg dose, P < 0.01).",Pharmacokinetics of terbinafine in young children treated for tinea capitis. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220086/),[h·ng] / [kg·mg·ml],2756,62285,DB00857,Terbinafine
,16220086,accumulation ratio,"A slight but significant reduction in apparent oral clearance was observed with increasing age (0.02 L/h/kg per yr) that likely accounts for the lesser degree of accumulation observed in children at steady state (accumulation ratio, 1.5 +/- 0.8 versus 2.3 +/- 0.6, P < 0.01).",Pharmacokinetics of terbinafine in young children treated for tinea capitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220086/),,1.5,62286,DB00857,Terbinafine
,16220086,accumulation ratio,"A slight but significant reduction in apparent oral clearance was observed with increasing age (0.02 L/h/kg per yr) that likely accounts for the lesser degree of accumulation observed in children at steady state (accumulation ratio, 1.5 +/- 0.8 versus 2.3 +/- 0.6, P < 0.01).",Pharmacokinetics of terbinafine in young children treated for tinea capitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220086/),,2.3,62287,DB00857,Terbinafine
,7780587,extraction efficiencies,"Due to the considerable differences in hydrophobicity between the compounds, extraction efficiencies ranged from 55 to 100%.",Simultaneous determination of terbinafine (Lamisil) and five metabolites in human plasma and urine by high-performance liquid chromatography using on-line solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7780587/),%,55 to 100,68275,DB00857,Terbinafine
,8739024,terminal half-life (t1/2),Terbinafine was found to have an average terminal half-life (t1/2) of approximately 3 weeks.,Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739024/),weeks,3,75102,DB00857,Terbinafine
,11745740,elimination half-life,"Terbinafine plasma concentrations declined in a triexponential fashion, with an estimated elimination half-life of 10 h.",Tissue distribution of terbinafine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745740/),h,10,76803,DB00857,Terbinafine
,11745740,clearance,The estimated clearance of terbinafine in rats was 2 L/h/kg and the volume of distribution at steady state was 6 L/kg.,Tissue distribution of terbinafine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745740/),[l] / [h·kg],2,76804,DB00857,Terbinafine
,11745740,volume of distribution at steady state,The estimated clearance of terbinafine in rats was 2 L/h/kg and the volume of distribution at steady state was 6 L/kg.,Tissue distribution of terbinafine in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745740/),[l] / [kg],6,76805,DB00857,Terbinafine
,11745740,K(p),"The preferential distribution of terbinafine to adipose and skin (K(p) = 49 and 45, respectively) was consistent with the lipophilicity of the drug.",Tissue distribution of terbinafine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745740/),,49,76806,DB00857,Terbinafine
,11745740,K(p),"The preferential distribution of terbinafine to adipose and skin (K(p) = 49 and 45, respectively) was consistent with the lipophilicity of the drug.",Tissue distribution of terbinafine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745740/),,45,76807,DB00857,Terbinafine
,11745740,K(p),Uptake of terbinafine into brain (K(p) = 1.3) and muscle (K(p) = 1.0) was significantly lower.,Tissue distribution of terbinafine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745740/),,1.3,76808,DB00857,Terbinafine
,11745740,K(p),Uptake of terbinafine into brain (K(p) = 1.3) and muscle (K(p) = 1.0) was significantly lower.,Tissue distribution of terbinafine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745740/),,1.0,76809,DB00857,Terbinafine
,34130394,area under the curve from time 0 to 24 h,"Mean area under the curve from time 0 to 24 h was 1,213 h × ng/ml (range 319-7,309), mean peak plasma concentration was 201.5 ng/ml (range 45.8-585.3), mean time to maximum plasma concentration was 1.26 h (range 1-4), mean residence time was 7.71 h (range 3.85-14.8), and mean terminal half-life was 5.35 h (range 2.67-9.83).",TERBINAFINE PHARMACOKINETICS FOLLOWING SINGLE-DOSE ORAL ADMINISTRATION IN RED-EARED SLIDER TURTLES (TRACHEMYS SCRIPTA ELEGANS): A PILOT STUDY. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34130394/),[h·ng] / [ml],"1,213",81877,DB00857,Terbinafine
,34130394,peak plasma concentration,"Mean area under the curve from time 0 to 24 h was 1,213 h × ng/ml (range 319-7,309), mean peak plasma concentration was 201.5 ng/ml (range 45.8-585.3), mean time to maximum plasma concentration was 1.26 h (range 1-4), mean residence time was 7.71 h (range 3.85-14.8), and mean terminal half-life was 5.35 h (range 2.67-9.83).",TERBINAFINE PHARMACOKINETICS FOLLOWING SINGLE-DOSE ORAL ADMINISTRATION IN RED-EARED SLIDER TURTLES (TRACHEMYS SCRIPTA ELEGANS): A PILOT STUDY. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34130394/),[ng] / [ml],201.5,81878,DB00857,Terbinafine
,34130394,time to maximum plasma concentration,"Mean area under the curve from time 0 to 24 h was 1,213 h × ng/ml (range 319-7,309), mean peak plasma concentration was 201.5 ng/ml (range 45.8-585.3), mean time to maximum plasma concentration was 1.26 h (range 1-4), mean residence time was 7.71 h (range 3.85-14.8), and mean terminal half-life was 5.35 h (range 2.67-9.83).",TERBINAFINE PHARMACOKINETICS FOLLOWING SINGLE-DOSE ORAL ADMINISTRATION IN RED-EARED SLIDER TURTLES (TRACHEMYS SCRIPTA ELEGANS): A PILOT STUDY. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34130394/),h,1.26,81879,DB00857,Terbinafine
,34130394,mean residence time,"Mean area under the curve from time 0 to 24 h was 1,213 h × ng/ml (range 319-7,309), mean peak plasma concentration was 201.5 ng/ml (range 45.8-585.3), mean time to maximum plasma concentration was 1.26 h (range 1-4), mean residence time was 7.71 h (range 3.85-14.8), and mean terminal half-life was 5.35 h (range 2.67-9.83).",TERBINAFINE PHARMACOKINETICS FOLLOWING SINGLE-DOSE ORAL ADMINISTRATION IN RED-EARED SLIDER TURTLES (TRACHEMYS SCRIPTA ELEGANS): A PILOT STUDY. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34130394/),h,7.71,81880,DB00857,Terbinafine
,34130394,terminal half-life,"Mean area under the curve from time 0 to 24 h was 1,213 h × ng/ml (range 319-7,309), mean peak plasma concentration was 201.5 ng/ml (range 45.8-585.3), mean time to maximum plasma concentration was 1.26 h (range 1-4), mean residence time was 7.71 h (range 3.85-14.8), and mean terminal half-life was 5.35 h (range 2.67-9.83).",TERBINAFINE PHARMACOKINETICS FOLLOWING SINGLE-DOSE ORAL ADMINISTRATION IN RED-EARED SLIDER TURTLES (TRACHEMYS SCRIPTA ELEGANS): A PILOT STUDY. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34130394/),h,5.35,81881,DB00857,Terbinafine
up to,17559730,residence time,The residence time of the film on the skin was up to 72 h after application (up to 12 h for the 1% cream).,"Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559730/),h,72,83617,DB00857,Terbinafine
up to,17559730,residence time,The residence time of the film on the skin was up to 72 h after application (up to 12 h for the 1% cream).,"Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559730/),h,12,83618,DB00857,Terbinafine
,17559730,t(max),The C(max) was observed as early as 1.5 h (t(max)).,"Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559730/),h,1.5,83619,DB00857,Terbinafine
,17559730,t(1/2)),SC levels were still detected after 13 days (24 ng/cm(2)) (t(1/2)) was 162 h).,"Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559730/),h,162,83620,DB00857,Terbinafine
,17559730,t(max),"Terbinafine 1% cream showed a similar t(max) (2 h) with a lower C(max) than terbinafine 1% FFS, and mean SC levels after 7 days of treatment were 46 ng/cm(2) (day 13).","Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559730/),h,2,83621,DB00857,Terbinafine
,17559730,SC levels,"Terbinafine 1% cream showed a similar t(max) (2 h) with a lower C(max) than terbinafine 1% FFS, and mean SC levels after 7 days of treatment were 46 ng/cm(2) (day 13).","Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559730/),[ng] / [cm(2],46,83622,DB00857,Terbinafine
,17559730,t(1/2),The t(1/2) was 68 h.,"Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559730/),h,68,83623,DB00857,Terbinafine
,24447130,particle size,"Mean particle size of the terbinafine hydrochloride transfersomes was 69.6 ± 1.23 nm, and the entrapment efficiency was 95.4% ± 0.51.",A novel drug delivery gel of terbinafine hydrochloride with high penetration for external use. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24447130/),nm,69.6,104750,DB00857,Terbinafine
,24447130,entrapment efficiency,"Mean particle size of the terbinafine hydrochloride transfersomes was 69.6 ± 1.23 nm, and the entrapment efficiency was 95.4% ± 0.51.",A novel drug delivery gel of terbinafine hydrochloride with high penetration for external use. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24447130/),%,95.4,104751,DB00857,Terbinafine
,24447130,content,The content of the gel was 4.45 ± 0.15 mg/g.,A novel drug delivery gel of terbinafine hydrochloride with high penetration for external use. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24447130/),,4.45,104752,DB00857,Terbinafine
,24447130,accumulated permeation,The accumulated permeation of the transfersomes gel in 12 h was 88.52 ± 4.06 µg cm-2 and the intracutaneous drug detention was 94.38 ± 5.26 µg cm-2.,A novel drug delivery gel of terbinafine hydrochloride with high penetration for external use. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24447130/),[μg] / [(cm)^2],88.52,104753,DB00857,Terbinafine
,24447130,drug detention,The accumulated permeation of the transfersomes gel in 12 h was 88.52 ± 4.06 µg cm-2 and the intracutaneous drug detention was 94.38 ± 5.26 µg cm-2.,A novel drug delivery gel of terbinafine hydrochloride with high penetration for external use. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24447130/),[μg] / [(cm)^2],94.38,104754,DB00857,Terbinafine
,33377208,Cmax,"Noncompartmental analyses of the data showed a Cmax (geometric mean) of 5.43 µg/ml, tmax (median) 1.0 hr and AUC0-∞ 29.70 mg h/L.",Pharmacokinetics of single dose oral Terbinafine in common shelducks (Tadorna tadorna). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33377208/),[μg] / [ml],5.43,113542,DB00857,Terbinafine
,33377208,tmax,"Noncompartmental analyses of the data showed a Cmax (geometric mean) of 5.43 µg/ml, tmax (median) 1.0 hr and AUC0-∞ 29.70 mg h/L.",Pharmacokinetics of single dose oral Terbinafine in common shelducks (Tadorna tadorna). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33377208/),h,1.0,113543,DB00857,Terbinafine
,33377208,AUC0-∞,"Noncompartmental analyses of the data showed a Cmax (geometric mean) of 5.43 µg/ml, tmax (median) 1.0 hr and AUC0-∞ 29.70 mg h/L.",Pharmacokinetics of single dose oral Terbinafine in common shelducks (Tadorna tadorna). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33377208/),[h·mg] / [l],29.70,113544,DB00857,Terbinafine
,33377208,Elimination half-life,Elimination half-life was 6.33 hr and MRT 6.61 hr.,Pharmacokinetics of single dose oral Terbinafine in common shelducks (Tadorna tadorna). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33377208/),h,6.33,113545,DB00857,Terbinafine
,33377208,MRT,Elimination half-life was 6.33 hr and MRT 6.61 hr.,Pharmacokinetics of single dose oral Terbinafine in common shelducks (Tadorna tadorna). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33377208/),h,6.61,113546,DB00857,Terbinafine
,18751504,AUC(0.48),"The AUC(0.48) of terbinafine was 5982.85 +/- 2449.17 and 6761.63 +/- 3140.33 ng x h/ml for the test and reference formulation, respectively.",Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751504/),[h·ng] / [ml],5982.85,120039,DB00857,Terbinafine
,18751504,AUC(0.48),"The AUC(0.48) of terbinafine was 5982.85 +/- 2449.17 and 6761.63 +/- 3140.33 ng x h/ml for the test and reference formulation, respectively.",Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751504/),[h·ng] / [ml],6761.63,120040,DB00857,Terbinafine
,18751504,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of terbinafine was 1656.25 +/- 623.18 ng/ml for the test and 1552.07 +/- 660.35 ng/ml for the reference product, respectively.",Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751504/),[ng] / [ml],1656.25,120041,DB00857,Terbinafine
,18751504,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of terbinafine was 1656.25 +/- 623.18 ng/ml for the test and 1552.07 +/- 660.35 ng/ml for the reference product, respectively.",Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751504/),[ng] / [ml],1552.07,120042,DB00857,Terbinafine
,8593011,peak concentrations,"Terbinafine was rapidly absorbed, with peak concentrations in plasma of 1.70 +/- 0.77 micrograms/ml occurring 1.2 +/- 0.3 h postdose.",Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593011/),[μg] / [ml],1.70,120867,DB00857,Terbinafine
,8593011,terminal deposition half-life,"Concentrations subsequently exhibited a triphasic decline, with a terminal deposition half-life of 16.5 +/- 2.8 days.",Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593011/),d,16.5,120868,DB00857,Terbinafine
,12069977,volume of distribution at steady state (V(ss)),The estimated volume of distribution at steady state (V(ss)) obtained from the PB-PK model agreed with the reported value of 11 liters/kg.,Physiologically based pharmacokinetic model for terbinafine in rats and humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069977/),[l] / [kg],11,124916,DB00857,Terbinafine
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.34,128355,DB00857,Terbinafine
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.06,128356,DB00857,Terbinafine
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.21,128357,DB00857,Terbinafine
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,5.8,128358,DB00857,Terbinafine
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,7.6,128359,DB00857,Terbinafine
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,6.7,128360,DB00857,Terbinafine
,21599768,Area under the curve (AUC) from time 0 to 24 h,"Area under the curve (AUC) from time 0 to 24 h was 15.4 μg·h/mL (range 5-27), maximal plasma concentration (C(max) ) was 3.5 μg/mL (range 3-4.9 μg/mL) and time to C(max) (T(max) ) was 3.6 h (range 2-6 h).",Terbinafine pharmacokinetics after single dose oral administration in the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599768/),[h·μg] / [ml],15.4,129679,DB00857,Terbinafine
,21599768,maximal plasma concentration (C(max) ),"Area under the curve (AUC) from time 0 to 24 h was 15.4 μg·h/mL (range 5-27), maximal plasma concentration (C(max) ) was 3.5 μg/mL (range 3-4.9 μg/mL) and time to C(max) (T(max) ) was 3.6 h (range 2-6 h).",Terbinafine pharmacokinetics after single dose oral administration in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599768/),[μg] / [ml],3.5,129680,DB00857,Terbinafine
,21599768,time to C(max) (T(max) ),"Area under the curve (AUC) from time 0 to 24 h was 15.4 μg·h/mL (range 5-27), maximal plasma concentration (C(max) ) was 3.5 μg/mL (range 3-4.9 μg/mL) and time to C(max) (T(max) ) was 3.6 h (range 2-6 h).",Terbinafine pharmacokinetics after single dose oral administration in the dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599768/),h,3.6,129681,DB00857,Terbinafine
,21599768,T > MIC,"The T > MIC was 17-18 h for Blastomyces dermatitidis, Histoplasma capsulatum and dermatophytes (Microsporum spp. and Trichophyton mentagrophytes), while the MIC for Sporothrix schenckii and Coccidioides immitis was exceeded for 9.5-11 h.",Terbinafine pharmacokinetics after single dose oral administration in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599768/),h,17-18,129682,DB00857,Terbinafine
exceeded,21599768,MIC,"The T > MIC was 17-18 h for Blastomyces dermatitidis, Histoplasma capsulatum and dermatophytes (Microsporum spp. and Trichophyton mentagrophytes), while the MIC for Sporothrix schenckii and Coccidioides immitis was exceeded for 9.5-11 h.",Terbinafine pharmacokinetics after single dose oral administration in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599768/),h,9.5-11,129683,DB00857,Terbinafine
,21599768,AUC/MIC,The AUC/MIC values ranged from 9 to 13 μg h/mL for these fungi.,Terbinafine pharmacokinetics after single dose oral administration in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599768/),[h·μg] / [ml],9 to 13,129684,DB00857,Terbinafine
,8573687,apparent terminal half-lives,"The apparent terminal half-lives of terbinafine, demethylterbinafine, and the two carboxy metabolites appear to be similar (approximately 25 h).","Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573687/),h,25,134115,DB00857,Terbinafine
,18226588,detection limit (S/N,The detection limit (S/N=3) was 2.5 x 10(-8 )M.,Voltammetric determination of terbinafine in biological fluid at glassy carbon electrode modified by cysteic acid/carbon nanotubes composite film. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18226588/),,3,151723,DB00857,Terbinafine
,18226588,detection limit (S/N,The detection limit (S/N=3) was 2.5 x 10(-8 )M.,Voltammetric determination of terbinafine in biological fluid at glassy carbon electrode modified by cysteic acid/carbon nanotubes composite film. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18226588/),M,2.5 x 10(-8 ),151724,DB00857,Terbinafine
,26286855,maximum concentration (Cmax,"Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),[μg] / [ml],23.59,159925,DB00857,Terbinafine
,26286855,maximum concentration (Cmax,"Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),[μg] / [ml],0.31,159926,DB00857,Terbinafine
,26286855,maximum concentration (Cmax,"Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),[μg] / [ml],0.30,159927,DB00857,Terbinafine
,26286855,maximum concentration (Cmax,"Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),[μg] / [ml],0.48,159928,DB00857,Terbinafine
,26286855,"half-life (t1/2 , d)","Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),,4.49,159929,DB00857,Terbinafine
,26286855,"half-life (t1/2 , d)","Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),,6.34,159930,DB00857,Terbinafine
,26286855,"half-life (t1/2 , d)","Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),,4.64,159931,DB00857,Terbinafine
,26286855,"half-life (t1/2 , d)","Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),,5.12,159932,DB00857,Terbinafine
,26286855,"time to maximum concentration (Tmax , d)","Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),,10.40,159933,DB00857,Terbinafine
,26286855,"time to maximum concentration (Tmax , d)","Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),,13.20,159934,DB00857,Terbinafine
,26286855,"time to maximum concentration (Tmax , d)","Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),,11.90,159935,DB00857,Terbinafine
,26286855,"time to maximum concentration (Tmax , d)","Relevant (mean ± standard deviation) parameters for TBF in serum, paw SC, thorax SC and sebum, respectively, were: maximum concentration (Cmax , μg/mL) 23.59 ± 10.41, 0.31 ± 0.26, 0.30 ± 0.32 and 0.48 ± 0.25; half-life (t1/2 , d) 4.49 ± 2.24, 6.34 ± 5.33, 4.64 ± 3.27 and 5.12 ± 3.33; time to maximum concentration (Tmax , d) 10.40 ± 6.98, 13.20 ± 5.16, 11.90 ± 8.62 and 10.60 ± 3.69.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),,10.60,159936,DB00857,Terbinafine
,26286855,MIC90,"The mean Cmax of all skin tissues (paw SC, thorax SC and sebum) barely exceeded the reported Malassezia MIC90, of 0.25 μg/mL, which indicates that doses higher than 30 mg/kg p.o. once daily may be necessary.",Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286855/),[μg] / [ml],0.25,159937,DB00857,Terbinafine
,7756158,terminal gamma-phase,"However, a longer terminal gamma-phase (at least 6 days) is observed, as in adults, after multiple dose administration, and this is related to elimination from the tissues.","Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756158/),d,6,163122,DB00857,Terbinafine
,27885696,half-life,"The half-life (geometric mean) was 8.38 and 10.76 h, for p.o. alone and p.o. with cimetidine, respectively.",Pharmacokinetics of oral terbinafine in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885696/),h,8.38,171821,DB00857,Terbinafine
,27885696,half-life,"The half-life (geometric mean) was 8.38 and 10.76 h, for p.o. alone and p.o. with cimetidine, respectively.",Pharmacokinetics of oral terbinafine in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885696/),h,10.76,171822,DB00857,Terbinafine
,27885696,maximum plasma concentrations,"The mean maximum plasma concentrations were 0.291 μg/mL at 1.54 h and 0.418 μg/mL at 1.28 h for p.o. alone and p.o. with cimetidine, respectively.",Pharmacokinetics of oral terbinafine in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885696/),[μg] / [ml],0.291,171823,DB00857,Terbinafine
,27885696,maximum plasma concentrations,"The mean maximum plasma concentrations were 0.291 μg/mL at 1.54 h and 0.418 μg/mL at 1.28 h for p.o. alone and p.o. with cimetidine, respectively.",Pharmacokinetics of oral terbinafine in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885696/),[μg] / [ml],0.418,171824,DB00857,Terbinafine
,23298433,AUC/MIC ratios,"Moreover, integration of in vivo pharmacokinetic data with the in vitro minimum inhibitory concentration (MIC) provided iodiconazole AUC/MIC ratios in rat dermis and blood of 347.7h and 18.8h, respectively, with an iodiconazole cream (2%) dosage of 0.033 g/cm² (3 cm×5 cm).","In vivo pharmacokinetics and in vitro antifungal activity of iodiconazole, a new triazole, determined by microdialysis sampling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23298433/),h,347.7,185112,DB00857,Terbinafine
,23298433,AUC/MIC ratios,"Moreover, integration of in vivo pharmacokinetic data with the in vitro minimum inhibitory concentration (MIC) provided iodiconazole AUC/MIC ratios in rat dermis and blood of 347.7h and 18.8h, respectively, with an iodiconazole cream (2%) dosage of 0.033 g/cm² (3 cm×5 cm).","In vivo pharmacokinetics and in vitro antifungal activity of iodiconazole, a new triazole, determined by microdialysis sampling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23298433/),h,18.8,185113,DB00857,Terbinafine
,11802108,ch,The method has a chromatographic run time of 5 minutes and was linear in the range 1.0 to 2000 ng/mL.,Terbinafine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802108/),min,5,191915,DB00857,Terbinafine
,20806657,peak mean,"After administration of 15 mg/kg terbinafine, mean (+/- SD) plasma concentration peaked in approximately 5 hours at 0.3 +/- 0.24 microg/mL, whereas a 30 mg/kg dose resulted in peak mean (+/- SD) plasma concentration of 1.2 +/- 0.40 microg/mL in 3 hours and a 60 mg/kg dose resulted in mean (+/- SD) concentration of 2.0 +/- 0.75 microg/mL in 5 hours.",Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20806657/),[μg] / [ml],1.2,193304,DB00857,Terbinafine
,20806657,volume of distribution,"The volume of distribution decreased with increasing doses, averaging 76.8 +/- 38.06 mL/kg for the 15 mg/kg dose and falling to 55.2 +/- 17.4 mL/kg for the 30 mg/kg dose.",Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20806657/),[ml] / [kg],76.8,193305,DB00857,Terbinafine
,20806657,volume of distribution,"The volume of distribution decreased with increasing doses, averaging 76.8 +/- 38.06 mL/kg for the 15 mg/kg dose and falling to 55.2 +/- 17.4 mL/kg for the 30 mg/kg dose.",Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20806657/),[ml] / [kg],55.2,193306,DB00857,Terbinafine
,20806657,half-life,"The harmonic mean (+/- SD) half-life was biphasic, with initial values of 14.7 +/- 6.67 hours, 17.5 +/- 8.7 hours, and 13.3 +/- 5.03 hours for 15, 30, and 60 mg/kg doses, respectively.",Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20806657/),h,14.7,193307,DB00857,Terbinafine
,20806657,half-life,"The harmonic mean (+/- SD) half-life was biphasic, with initial values of 14.7 +/- 6.67 hours, 17.5 +/- 8.7 hours, and 13.3 +/- 5.03 hours for 15, 30, and 60 mg/kg doses, respectively.",Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20806657/),h,17.5,193308,DB00857,Terbinafine
,20806657,half-life,"The harmonic mean (+/- SD) half-life was biphasic, with initial values of 14.7 +/- 6.67 hours, 17.5 +/- 8.7 hours, and 13.3 +/- 5.03 hours for 15, 30, and 60 mg/kg doses, respectively.",Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20806657/),h,13.3,193309,DB00857,Terbinafine
,20806657,final elimination,"A rapid first-elimination phase was followed by a slower second phase, and final elimination was estimated to be 161 +/- 78.2 and 147 +/- 65.6 hours for 15 and 30 mg/kg doses, respectively.",Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20806657/),h,161,193310,DB00857,Terbinafine
,20806657,final elimination,"A rapid first-elimination phase was followed by a slower second phase, and final elimination was estimated to be 161 +/- 78.2 and 147 +/- 65.6 hours for 15 and 30 mg/kg doses, respectively.",Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20806657/),h,147,193311,DB00857,Terbinafine
,20806657,minimum inhibitory concentration,Calculations based on pharmacokinetic parameter values indicated that a dosage of 22 mg/kg terbinafine q24h would result in steady-state trough plasma concentrations above the minimum inhibitory concentration of terbinafine (0.8-1.6 microg/mL).,Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20806657/),[μg] / [ml],0.8-1.6,193312,DB00857,Terbinafine
,8092721,Mycological cure rate,"Mycological cure rate was 92 p. 100, and complete cure rate was 86 p. 100.",[Efficacy and tolerance of terbinafine (Lamisil) in a series of 50 cases of dermatophyte onychomycoses]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092721/),p,92,200527,DB00857,Terbinafine
,8092721,complete cure rate,"Mycological cure rate was 92 p. 100, and complete cure rate was 86 p. 100.",[Efficacy and tolerance of terbinafine (Lamisil) in a series of 50 cases of dermatophyte onychomycoses]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092721/),p,86,200528,DB00857,Terbinafine
,8092721,time to mycological cure,The mean time to mycological cure was 22.4 weeks and the mean time to complete cure was 31.5 weeks.,[Efficacy and tolerance of terbinafine (Lamisil) in a series of 50 cases of dermatophyte onychomycoses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092721/),weeks,22.4,200529,DB00857,Terbinafine
,8092721,time to complete cure,The mean time to mycological cure was 22.4 weeks and the mean time to complete cure was 31.5 weeks.,[Efficacy and tolerance of terbinafine (Lamisil) in a series of 50 cases of dermatophyte onychomycoses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092721/),weeks,31.5,200530,DB00857,Terbinafine
,28674244,unbound Ki,"Terbinafine competitively inhibited amitriptyline or nortriptyline E-10-hydroxylation, with unbound Ki values of 13.7 and 12.4 nM, respectively.",Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28674244/),nM,13.7,209869,DB00857,Terbinafine
,28674244,unbound Ki,"Terbinafine competitively inhibited amitriptyline or nortriptyline E-10-hydroxylation, with unbound Ki values of 13.7 and 12.4 nM, respectively.",Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28674244/),nM,12.4,209870,DB00857,Terbinafine
,8593713,Maximum terbinafine levels,"Maximum terbinafine levels of 0.52 and 1.01 micrograms/g were measured after 18 weeks in the 6- and 12-week treatment groups, respectively.",Nail incorporation kinetics of terbinafine in onychomycosis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593713/),,0.52,211595,DB00857,Terbinafine
,8593713,Maximum terbinafine levels,"Maximum terbinafine levels of 0.52 and 1.01 micrograms/g were measured after 18 weeks in the 6- and 12-week treatment groups, respectively.",Nail incorporation kinetics of terbinafine in onychomycosis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593713/),,1.01,211596,DB00857,Terbinafine
,11204359,overall clinical improvement rate,"The overall clinical improvement rate was 95.5% (100% for true-, 80% for partial- and 96.2% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,95.5,213233,DB00857,Terbinafine
,11204359,overall clinical improvement rate,"The overall clinical improvement rate was 95.5% (100% for true-, 80% for partial- and 96.2% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,100,213234,DB00857,Terbinafine
,11204359,overall clinical improvement rate,"The overall clinical improvement rate was 95.5% (100% for true-, 80% for partial- and 96.2% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,80,213235,DB00857,Terbinafine
,11204359,overall fungal eradication rate,"The overall fungal eradication rate was 88.6% (75% for true-, 100% for partial- and 88.5% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,88.6,213236,DB00857,Terbinafine
,11204359,overall fungal eradication rate,"The overall fungal eradication rate was 88.6% (75% for true-, 100% for partial- and 88.5% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,75,213237,DB00857,Terbinafine
,11204359,overall fungal eradication rate,"The overall fungal eradication rate was 88.6% (75% for true-, 100% for partial- and 88.5% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,100,213238,DB00857,Terbinafine
,11204359,overall fungal eradication rate,"The overall fungal eradication rate was 88.6% (75% for true-, 100% for partial- and 88.5% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,88.5,213239,DB00857,Terbinafine
,11204359,overall efficacy rate,"The overall efficacy rate was 88.6% (75% for true-, 100% for partial- and 88.5% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,88.6,213240,DB00857,Terbinafine
,11204359,overall efficacy rate,"The overall efficacy rate was 88.6% (75% for true-, 100% for partial- and 88.5% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,75,213241,DB00857,Terbinafine
,11204359,overall efficacy rate,"The overall efficacy rate was 88.6% (75% for true-, 100% for partial- and 88.5% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,100,213242,DB00857,Terbinafine
,11204359,overall efficacy rate,"The overall efficacy rate was 88.6% (75% for true-, 100% for partial- and 88.5% for quasi-hyperkeratotic type).",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),%,88.5,213243,DB00857,Terbinafine
,11204359,Drug concentrations,"Drug concentrations in the horny layer were 170.3, 228.5 and 249.2 ng mg-1, respectively, 2, 4 and 12 weeks after starting the treatment.",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),[ng] / [mg],170.3,213244,DB00857,Terbinafine
,11204359,Drug concentrations,"Drug concentrations in the horny layer were 170.3, 228.5 and 249.2 ng mg-1, respectively, 2, 4 and 12 weeks after starting the treatment.",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),[ng] / [mg],228.5,213245,DB00857,Terbinafine
,11204359,Drug concentrations,"Drug concentrations in the horny layer were 170.3, 228.5 and 249.2 ng mg-1, respectively, 2, 4 and 12 weeks after starting the treatment.",Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204359/),[ng] / [mg],249.2,213246,DB00857,Terbinafine
,23615773,zeta potential,"Spherical, discrete NPs were successfully developed with mean particle size and zeta potential ranging from 73.29 to 320.15 nm and +20.51 to +40.32 mV, respectively.",Positively charged polymeric nanoparticle reservoirs of terbinafine hydrochloride: preclinical implications for controlled drug delivery in the aqueous humor of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23615773/),mv,20,218843,DB00857,Terbinafine
,23057672,T(max),"In addition, K(SC/veh) and D/L² at T(max) of 2 h were used to predict the AUC presented the value of 4.7481 %h whereas the true value calculated from pharmacokinetic software provided the value of 5.9311 %h differing from each other in approximate of 20%.",In vitro-in vivo correlation study for the dermatopharmacokinetics of terbinafine hydrochloride topical cream. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23057672/),h,2,220533,DB00857,Terbinafine
,2612536,t1/2,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),h,11.7,228131,DB00857,Terbinafine
,2612536,total plasma,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],38.5,228132,DB00857,Terbinafine
,2612536,renal clearance,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],1.6,228133,DB00857,Terbinafine
,2612536,clearance rates,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],12.3,228134,DB00857,Terbinafine
,2612536,CLM,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],12.3,228135,DB00857,Terbinafine
,2612536,CLM,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],4.2,228136,DB00857,Terbinafine
,2612536,CLM,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],6.7,228137,DB00857,Terbinafine
,17112806,plasma clearance,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),[ml] / [kg·min],4.4,232835,DB00857,Terbinafine
,17112806,plasma clearance,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),[ml] / [kg·min],0.67,232836,DB00857,Terbinafine
,17112806,elimination half-life,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),h,1.5,232837,DB00857,Terbinafine
,17112806,elimination half-life,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),h,6.6,232838,DB00857,Terbinafine
,20597218,peak plasma concentrations,"Mean plasma concentrations of terbinafine peaked in approximately 4 hrs at 0.11 +/- 0.017 microg/ml (mean +/- SD) following administration of 3 mg/kg terbinafine, while 7 mg/kg and 15 mg/kg dosages resulted in peak plasma concentrations of 0.37 +/- 0.105 and 0.33 +/- 0.054 microg/ml, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),[μg] / [ml],0.37,237117,DB00857,Terbinafine
,20597218,peak plasma concentrations,"Mean plasma concentrations of terbinafine peaked in approximately 4 hrs at 0.11 +/- 0.017 microg/ml (mean +/- SD) following administration of 3 mg/kg terbinafine, while 7 mg/kg and 15 mg/kg dosages resulted in peak plasma concentrations of 0.37 +/- 0.105 and 0.33 +/- 0.054 microg/ml, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),[μg] / [ml],0.33,237118,DB00857,Terbinafine
,20597218,volume of distribution,"The volume of distribution increased with increasing dosages, being 37 +/- 28.5, 40 +/- 28.1, and 52 +/- 18.6 mg/L for 3, 7, and 15 mg/kg doses, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),[mg] / [l],37,237119,DB00857,Terbinafine
,20597218,volume of distribution,"The volume of distribution increased with increasing dosages, being 37 +/- 28.5, 40 +/- 28.1, and 52 +/- 18.6 mg/L for 3, 7, and 15 mg/kg doses, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),[mg] / [l],40,237120,DB00857,Terbinafine
,20597218,volume of distribution,"The volume of distribution increased with increasing dosages, being 37 +/- 28.5, 40 +/- 28.1, and 52 +/- 18.6 mg/L for 3, 7, and 15 mg/kg doses, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),[mg] / [l],52,237121,DB00857,Terbinafine
,20597218,initial terminal half-life (t(1/2)),"The mean half-life was biphasic with initial terminal half-life (t(1/2)) values of 9.9 +/- 4.5, 17.2 +/- 4.9 and 16.9 +/- 5.4 hrs, for 3, 7, and 15 mg/kg doses, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),h,9.9,237122,DB00857,Terbinafine
,20597218,initial terminal half-life (t(1/2)),"The mean half-life was biphasic with initial terminal half-life (t(1/2)) values of 9.9 +/- 4.5, 17.2 +/- 4.9 and 16.9 +/- 5.4 hrs, for 3, 7, and 15 mg/kg doses, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),h,17.2,237123,DB00857,Terbinafine
,20597218,initial terminal half-life (t(1/2)),"The mean half-life was biphasic with initial terminal half-life (t(1/2)) values of 9.9 +/- 4.5, 17.2 +/- 4.9 and 16.9 +/- 5.4 hrs, for 3, 7, and 15 mg/kg doses, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),h,16.9,237124,DB00857,Terbinafine
,20597218,final elimination,"A rapid first elimination phase was followed by a slower second phase, and final elimination was estimated to be 136 +/- 9.7 and 131 +/- 9.9 hrs, for 7 and 15 mg/kg doses, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),h,136,237125,DB00857,Terbinafine
,20597218,final elimination,"A rapid first elimination phase was followed by a slower second phase, and final elimination was estimated to be 136 +/- 9.7 and 131 +/- 9.9 hrs, for 7 and 15 mg/kg doses, respectively.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),h,131,237126,DB00857,Terbinafine
above,20597218,minimum inhibitory concentration,"Calculations based on pharmacokinetic parameter values indicate that a 15 mg/kg terbinafine q24h dosage regimen would result in steady-state trough plasma concentrations above the minimum inhibitory concentration (0.8-1.6 microg/ ml), and this dosage is recommended as a potential treatment option for aspergillosis in penguins.",Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20597218/),[μg] / [ml],0.8-1.6,237127,DB00857,Terbinafine
,28029293,Tissue terminal half-life,Tissue terminal half-life ranged from 14 to 22 days.,Pharmacokinetics of terbinafine in little brown myotis (Myotis lucifugus) infected with Pseudogymnoascus destructans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28029293/),d,14 to 22,244275,DB00857,Terbinafine
,29566178,MLC,"The MLC of TBF for zoosporangia was 100 μg/ml for 2 h, while the minimal inhibitory concentration was 2 μg/ml, suggesting that the drug concentration absorbed during 5 min treatments is not sufficient to cure high Bd burdens.",The efficacy and pharmacokinetics of terbinafine against the frog-killing fungus (Batrachochytrium dendrobatidis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566178/),[μg] / [ml],100,252582,DB00857,Terbinafine
,29566178,minimal inhibitory concentration,"The MLC of TBF for zoosporangia was 100 μg/ml for 2 h, while the minimal inhibitory concentration was 2 μg/ml, suggesting that the drug concentration absorbed during 5 min treatments is not sufficient to cure high Bd burdens.",The efficacy and pharmacokinetics of terbinafine against the frog-killing fungus (Batrachochytrium dendrobatidis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566178/),[μg] / [ml],2,252583,DB00857,Terbinafine
less,29566178,half-life,"A higher dose of 0.02% TBF resulted in 78% of animals cured; however, clearance was not achieved in all individuals due to low TBF skin persistence, as the half-life was less than 2 h.",The efficacy and pharmacokinetics of terbinafine against the frog-killing fungus (Batrachochytrium dendrobatidis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566178/),h,2,252584,DB00857,Terbinafine
,17284933,peak,"After topical administration, the concentration of terbinafine increased gradually, reached a peak (1.39 microg/ml at 30 min in the cornea and 82.9 ng/ml at 30 min in aqueous humor, respectively) and then decreased.",Pharmacokinetics of terbinafine in the rabbit ocular tissues after topical administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284933/),[μg] / [ml],1.39,263680,DB00857,Terbinafine
,17284933,peak,"After topical administration, the concentration of terbinafine increased gradually, reached a peak (1.39 microg/ml at 30 min in the cornea and 82.9 ng/ml at 30 min in aqueous humor, respectively) and then decreased.",Pharmacokinetics of terbinafine in the rabbit ocular tissues after topical administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17284933/),[ng] / [ml],82.9,263681,DB00857,Terbinafine
,11475469,nail : plasma ratio,The nail : plasma ratio stabilises at around 1 by week 18 of treatment.,Pharmacokinetics of antifungal agents in onychomycoses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),,1,264431,DB00857,Terbinafine
,11475469,elimination half-life,"The elimination half-life of itraconazole from nails is long, ranging from 32 to 147 days.",Pharmacokinetics of antifungal agents in onychomycoses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),d,32 to 147,264432,DB00857,Terbinafine
,11475469,time to reach effective concentrations,"Terbinafine is well absorbed from the gastrointestinal tract, and the time to reach effective concentrations in nail is 1 to 2 weeks.",Pharmacokinetics of antifungal agents in onychomycoses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),weeks,1 to 2,264433,DB00857,Terbinafine
,11475469,half-life,"The half-life is from 24 to 156 days, explaining the observed persistence of terbinafine in nails for longer than 252 days.",Pharmacokinetics of antifungal agents in onychomycoses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),d,24 to 156,264434,DB00857,Terbinafine
,11475469,nail : plasma ratios,"The uptake of fluconazole by nail increases with the length of treatment, and nail : plasma ratios are generally 1.5 to 2 at steady state.",Pharmacokinetics of antifungal agents in onychomycoses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),,1.5 to 2,264435,DB00857,Terbinafine
,11475469,half-life,"Fluconazole concentrations fall slowly after the drug is stopped, with a half-life of 50 to 87 days, and fluconazole is still detectable in nails 5 months after the end of treatment.",Pharmacokinetics of antifungal agents in onychomycoses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),d,50 to 87,264436,DB00857,Terbinafine
≤,25605358,MIC,"We report here that the investigational agent VT-1161 displays potent in vitro antifungal activity against dermatophytes, with MIC values in the range of ≤0.016 to 0.5 μg/ml.",VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25605358/),[μg] / [ml],0,265941,DB00857,Terbinafine
,25605358,MIC,"VT-1161 was distributed into skin and hair, with plasma and tissue concentrations in all treatment and regimen groups ranging from 0.8 to 40 μg/ml (or μg/g), at or above the MIC against the isolate used in the model (0.5 μg/ml).",VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25605358/),[μg] / [ml],0.5,265942,DB00857,Terbinafine
,29466046,percentage absorption,"RESULTS During the 24-hour experiment, mean ± SD percentage absorption without the presence of synthetic canine cerumen was 0.28 ± 0.09% for 3H-betamethasone acetate, 0.06 ± 0.06% for florfenicol, and 0.06 ± 0.02% for 14C-terbinafine hydrochloride.","Impact of synthetic canine cerumen on in vitro penetration of auricular skin of dogs by florfenicol, terbinafine, and betamethasone acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466046/),%,0.28,272299,DB00857,Terbinafine
,29466046,percentage absorption,"RESULTS During the 24-hour experiment, mean ± SD percentage absorption without the presence of synthetic canine cerumen was 0.28 ± 0.09% for 3H-betamethasone acetate, 0.06 ± 0.06% for florfenicol, and 0.06 ± 0.02% for 14C-terbinafine hydrochloride.","Impact of synthetic canine cerumen on in vitro penetration of auricular skin of dogs by florfenicol, terbinafine, and betamethasone acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466046/),%,0.06,272300,DB00857,Terbinafine
,29466046,percentage absorption,"RESULTS During the 24-hour experiment, mean ± SD percentage absorption without the presence of synthetic canine cerumen was 0.28 ± 0.09% for 3H-betamethasone acetate, 0.06 ± 0.06% for florfenicol, and 0.06 ± 0.02% for 14C-terbinafine hydrochloride.","Impact of synthetic canine cerumen on in vitro penetration of auricular skin of dogs by florfenicol, terbinafine, and betamethasone acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29466046/),%,0.06,272301,DB00857,Terbinafine
